CINECA IRIS Institutional Research Information System

MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.397
EU - Europa 7.219
AS - Asia 3.021
AF - Africa 160
SA - Sud America 60
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 29
Totale 18.932
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.239
CN - Cina 2.156
DE - Germania 1.081
SE - Svezia 1.002
IT - Italia 971
IE - Irlanda 926
UA - Ucraina 771
FR - Francia 627
FI - Finlandia 435
AT - Austria 433
KR - Corea 364
GB - Regno Unito 291
PL - Polonia 225
VN - Vietnam 156
CA - Canada 133
SN - Senegal 112
IN - India 105
BE - Belgio 75
DK - Danimarca 58
JP - Giappone 58
NL - Olanda 57
GR - Grecia 50
RU - Federazione Russa 49
AU - Australia 42
BR - Brasile 32
EU - Europa 26
BY - Bielorussia 25
ES - Italia 24
TR - Turchia 24
CH - Svizzera 23
HK - Hong Kong 22
UZ - Uzbekistan 22
PT - Portogallo 20
MX - Messico 19
TW - Taiwan 19
SG - Singapore 14
ZA - Sudafrica 14
NO - Norvegia 13
TH - Thailandia 13
MU - Mauritius 12
RO - Romania 12
IR - Iran 11
SA - Arabia Saudita 11
HU - Ungheria 10
ID - Indonesia 10
CL - Cile 9
RS - Serbia 9
CZ - Repubblica Ceca 8
MK - Macedonia 8
NG - Nigeria 8
CO - Colombia 7
LU - Lussemburgo 6
PK - Pakistan 6
AR - Argentina 5
EG - Egitto 5
IL - Israele 5
PE - Perù 5
DZ - Algeria 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AM - Armenia 3
HR - Croazia 3
KZ - Kazakistan 3
MA - Marocco 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
CU - Cuba 2
HN - Honduras 2
IQ - Iraq 2
LV - Lettonia 2
SI - Slovenia 2
A1 - Anonimo 1
BD - Bangladesh 1
BG - Bulgaria 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
GI - Gibilterra 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 18.932
Salva come PNG Salva come JPEG
Città #
Beijing 1.693
Chandler 1.226
Dublin 923
Jacksonville 520
Houston 447
Vienna 430
Ann Arbor 410
Villeurbanne 353
Medford 322
Nyköping 316
Fairfield 298
Dearborn 290
Princeton 280
Wilmington 263
Torino 226
Warsaw 215
Woodbridge 191
San Mateo 182
Ashburn 157
Redwood City 125
Seattle 121
Fremont 117
Milan 113
Cambridge 105
Pisa 96
Dong Ket 93
Boston 78
Boardman 76
Toronto 67
Turin 67
Washington 66
Brussels 65
Munich 59
Shanghai 50
Düsseldorf 44
Hefei 42
Norwalk 40
Falls Church 36
Nanjing 36
Verona 36
Nürnberg 35
Mountain View 32
Rome 32
Guangzhou 30
Hangzhou 28
New York 28
Phoenix 27
Paris 26
Kunming 25
Lachine 25
Tokyo 25
Chengdu 24
San Diego 24
Philadelphia 21
Raritan 20
Jinan 16
Hebei 15
Taipei 15
Chennai 14
Duncan 14
Nanchang 14
Dallas 13
Changsha 12
Des Moines 12
Ottawa 12
Wuhan 12
San Jose 11
Shenyang 11
Central District 10
Florence 10
Hanover 10
Hyderabad 10
London 10
Piemonte 10
Rotterdam 10
Seoul 10
Amsterdam 9
Bologna 9
Den Haag 9
Leawood 9
Mexico 9
Palermo 9
Zhengzhou 9
Abuja 8
Fuzhou 8
Lisbon 8
Mcallen 8
Provo 8
Silver Spring 8
Upper Marlboro 8
Chongqing 7
Detroit 7
Istanbul 7
Jakarta 7
Marseille 7
Montréal 7
Piacenza 7
Rochester 7
Tucson 7
Bengaluru 6
Totale 11.115
Salva come PNG Salva come JPEG
Nome #
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 400
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 377
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 312
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 280
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 261
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 253
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 237
Chicago 2014 - 30 years of γδ T cells 231
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 202
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 189
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 180
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 171
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 169
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 169
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 151
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 149
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 149
null 148
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 128
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 127
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 124
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 124
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 121
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 118
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 116
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 114
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 111
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 110
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 110
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 110
Effective anti-tumor immunomodulatory properties of zoledronic acid 109
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 109
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 106
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 105
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 105
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 104
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 104
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 104
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 103
The tryptophan metabolism in the immune dysregulation of multiple myeloma 102
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 99
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 99
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 99
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 98
Is there a role for allografting in myeloma ?: an update of a comparative study 97
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 97
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 96
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 94
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 94
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 94
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 94
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 93
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 92
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 91
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 90
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 89
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 89
Difference in polyamine transport in human B and T lymphocytes. 88
[Idiotypic study of human myeloma] 88
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 88
Cytobiological studies in multiple myeloma. 87
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 87
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 87
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 86
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 86
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 84
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 84
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 84
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 84
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 83
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 83
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. 82
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 82
Cyclosporin A and dipyridamole: an effective combination against the generation of cytotoxic T lymphocytes (CTL). 81
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 81
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 81
null 80
Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. 79
Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0-tetradecanoilphorbol-13-acetate (TPA). 79
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 79
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 79
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 79
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 79
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 79
Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. 78
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 78
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 78
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 78
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 77
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 77
[Prognostic factors in multiple myeloma] 75
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 75
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 75
Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. 74
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 74
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 74
CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. 73
Human myeloma: several subsets of circulating lymphocytes express plasma cell-associated antigens. 73
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma 73
Totale 11.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.695
article - articoli 0
book - libri 0
conference - conferenze 16.161
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.856
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.542 0 0 0 41 102 155 98 273 98 200 390 185
2019/20202.598 79 117 147 250 202 461 359 152 221 251 207 152
2020/20212.691 271 155 170 156 291 125 175 134 321 209 377 307
2021/20223.010 108 89 91 218 123 57 463 159 104 326 648 624
2022/20234.036 414 321 92 347 353 992 362 263 425 134 210 123
2023/2024722 234 362 122 4 0 0 0 0 0 0 0 0
Totale 19.762